The Vanguard Group 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-29 11:22 am Purchase | 2025-06-30 | 13G | Aclaris Therapeutics, Inc. ACRS | The Vanguard Group | 6,662,063 6.150% | 1,691,809 (+34.04%) | Filing |
| 2025-04-30 10:53 am Purchase | 2025-03-31 | 13G | Aclaris Therapeutics, Inc. ACRS | The Vanguard Group | 4,970,254 4.600% | 248,367 (+5.26%) | Filing |
| 2024-02-13 4:55 pm Purchase | 2023-12-29 | 13G | Aclaris Therapeutics, Inc. ACRS | The Vanguard Group | 4,721,887 6.670% | 4,721,887 (New Position) | Filing |